Treating neovascular age-related Macular Degeneration with Aflibercept: a pilot 24 month, multi- centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen.

Trial Profile

Treating neovascular age-related Macular Degeneration with Aflibercept: a pilot 24 month, multi- centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms MATE
  • Most Recent Events

    • 18 Jul 2016 Planned End Date changed from 1 Jun 2016 to 30 Sep 2016.
    • 05 Dec 2015 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as reported by United Kingdom ClinicalResearch Network record.
    • 04 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top